Global Migraine Treatment Industry to Achieve US$ 4.74 Billion by 2033, Propelled by a Steady 4% Compound Annual Growth Rate | FMI

The Global Migraine Treatments Industry is on the brink of a significant upswing, fuelled by heightened awareness of the condition and notable advancements in treatment options. According to a comprehensive report by Future Market Insights, the market is anticipated to experience a steady compound annual growth rate (CAGR) of 4% from 2023 to 2033.

Migraine, characterized by debilitating headaches and accompanied by symptoms such as nausea, vomiting, and sensitivity to light and sound, imposes a substantial burden on individuals, affecting their work, social activities, and daily routines. The rising prevalence of this condition has spurred research and development efforts, leading to remarkable breakthroughs in migraine treatment.

Recent years have witnessed a paradigm shift in migraine treatment strategies, with the introduction of innovative medications and non-pharmacological approaches. This influx of novel and better-tolerated treatment options is expected to be a key driver behind the projected growth in the migraine treatments market. Patients, seeking more effective solutions, are likely to contribute significantly to the increasing demand for these advanced treatments.

Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16751

Key Takeaways from the Global Migraine Treatment Industry Study

• From 2018 to 2022, the migraine treatments market grew at a CAGR of 3%.
• The Global Migraine Treatment Industry is expected to grow with a 4% CAGR from 2023 to 2033.
• As of 2033, the migraine treatments Market is expected to reach US$ 4.74 Billion.
• According to the FMI analysis, hospitals account for the largest market share.
• North America is expected to possess 40% market share for the migraine treatments market.
• The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering migraine treatments.” says an FMI analyst

Global Migraine Treatment Industry Competition

Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.

• In November 2022, A team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.

Reach Out to Our Analyst For Your Queries https://www.futuremarketinsights.com/ask-question/rep-gb-16751

In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson’s disease.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global migraine treatments market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights based on Drug Class, Route of Administration, Treatment, Distribution Channel & Region.

Key Segments Profiled in the Global Migraine Treatment Industry Survey

Drug Class:

• Zavegepant
• Atogepant
• Zolmitriptan

Route of Administration:

• Oral
• Parenteral
• Nasal Sprays

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Treatment:

• Abortive Medicine
• Preventive Medicine

Grab Your Report on Discount Before It’s Gone! https://www.futuremarketinsights.com/request-discount/rep-gb-16751

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube